Profile
QNTM ZTS TAK HLN TEVA NBIX
Company Name Quantum BioPharma Ltd. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $42.19M $63.86B $42.38B $41.59B $23.49B $14.24B
Employees 0.00K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Zeeshan Saeed Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
QNTM ZTS TAK HLN TEVA NBIX
Quant Rating Score 1 3 3 3 2 4
Quant Rating Strong Sell Neutral Neutral Neutral Sell Buy
Trading
QNTM ZTS TAK HLN TEVA NBIX
Last Close $11.07 $144.09 $13.44 $9.27 $20.48 $143.21
High 52 $35 $181.95 $15.52 $11.41 $22.77 $153.29
Low 52 $2.9 $141.11 $12.89 $8.73 $12.82 $87.59
Price vs. 52 Week High -68.37 % -20.81 % -13.4 % -18.76 % -10.06 % -6.58 %
Price vs. 52 Week Low 281.72 % 2.11 % 4.27 % 6.19 % 59.75 % 63.5 %
Total Return
QNTM ZTS TAK HLN TEVA NBIX
1 Month Return -38.64 % -1.69 % -6.93 % 4.33 % 2.14 % 4.75 %
3 Month Return -53.29 % -2.23 % -5.08 % -4.04 % 33.16 % 11.09 %
6 Month Return 42.43 % -8.48 % -12.27 % -13.36 % 26.5 % 30.57 %
9 Month Return 255.95 % -15.69 % 0.37 % -2.11 % 15.51 % -5.67 %
YTD Return 200.82 % -11.56 % 1.51 % -2.83 % -7.08 % 4.92 %
1 Year Return 128.72 % -20.81 % -3.72 % -4.73 % 11 % 17.18 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
QNTM ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.34 % 4.77 % 1.57 % - -
Dividend Paid and Capex Coverage Ration (TTM) -3497881.93 % 1.89 % 2.01 % 2.01 % 2.78 % 14.57 %
Dividend Per Share (TTM) - 1.93 % 198 % 0.06 % - -
Payout Ratio (TTM) - 32.08 % 226.17 % 27.27 % - -
Growth
QNTM ZTS TAK HLN TEVA NBIX
Asset Growth -2.03 % 0.76 % -9.55 % 14.37 %
Gross Profit Growth - -0.19 % 5.47 % 25.65 %
Revenue Growth - -0.61 % 4.4 % 24.81 %
Revenue 3 Year - 19.01 % 1.52 % 95.79 %
Revenue 5 Year - 33.95 % -5.5 % 172.74 %
Revenue 10 Year - 33.95 % -38.45 % -
EBIT Growth 18.44 % 13.52 % -167.63 % 55.17 %
Net Income Growth 20.66 % 37.46 % -193.2 % 36.68 %
Net Income 3 Yeari Growth Per Share 80.97 % 4.91 % -482.97 % 258.91 %
Net Income 5 Yeari Growth Per Share 96.53 % 122.63 % -58.26 % 741.83 %
Net Income 10 Yeari Growth Per Share -3746.69 % 122.63 % -140.46 % 518.75 %
Operating Income Growth 32.17 % 10.52 % -169.98 % 127.38 %
Operating Cash Flow Growth (CFG) 36.49 % 9.57 % -8.85 % 52.71 %
Operating 3 Year CFG 84.33 % 71.6 % 52.26 % 118.72 %
Operating 5 Year CFG 95.21 % 196.04 % 123.59 % 269.64 %
Operating 10 Year CFG -962912.98 % 196.04 % -81.66 % 1038.19 %
EPS Growth 57.5 % 33.33 % -190 % 32.81 %
EPS Diluted Growth 57.5 % 33.33 % -190 % 33.2 %
Book Value Per Share -56.68 % -1.63 % -30.36 % 12.91 %
Share Holder 3 Year Equity Growth Per Share -89.97 % -37.97 % -49 % 77.59 %
Share Holder 5 Year Equity Growth Per Share -96.98 % -40.16 % -62.86 % 271.08 %
Share Holder 10 Year Equity Growth Per Share 1847.3 % -40.16 % -82.6 % 821.72 %
Dividend Per Share Growth - 49.01 % - -
Dividend 3 Year Growth Per Share - -49.79 % - -
Dividend 5 Year Growth Per Share - -49.97 % -100 % -
Dividend 10 Year Growth Per Share - -49.97 % -100 % -
Debt Growth 143.2 % 6.83 % -10.29 % 6.23 %
Free Cash Flow Growth 36.49 % 16.27 % -11.05 % 54.09 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2024
Profitability
QNTM ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM - 70.03 % 52.77 % 61.81 % 49.6 % 98.37 %
Return on Assets TTM -176.45 % 18.04 % 0.98 % 4.78 % -0.39 % 10.03 %
Return on Equity TTM -289.71 % 53.21 % 1.95 % 9.4 % -2.58 % 15.82 %
Return on Capital Employed TTM -911.13 % 31.67 % 4.8 % 8.34 % 3.16 % 15.17 %
Net Income Per EBT TTM 96.57 % 78.72 % 72.4 % 76.52 % 222.54 % 68.09 %
EBT Per Ebit TTM 149.86 % 94.26 % 33.29 % 88.09 % -7.94 % 114.25 %
EBIT Per Revenue TTM - 37.51 % 12.68 % 20.49 % 5.38 % 20.51 %
Cash Flow To Debt Ratio TTM -463.27 % 43.13 % 22.35 % 12.02 % 7.93 % 148.65 %
Receivables Turnover TTM - 6.09 6.59 5.14 4.67 3.69
Payables Turnover TTM 0.19 5.54 5.02 1.18 3.35 0.37
Inventory Turnover TTM 4.72 1.15 1.71 3.72 2.4 0.63
Fixed Asset Turnover TTM - 244.46 % 229.02 % 589.57 % 321.73 % 473.81 %
Asset Turnover TTM - 64.82 % 31.99 % 34.62 % 41.43 % 62.89 %
Operating Cash Flow Per Share TTM -3.47 6.58 643.53 0.11 1.21 6.41
Free Cash Flow Per Share TTM -3.47 4.99 521.29 0.1 0.78 5.97
Cash Per Share TTM 50.59 % 322.4 % 22368.59 % 7.46 % 188.4 % 1121.53 %
Operating Cash Flow Sales Ratio TTM - 31.21 % 22.48 % 9.32 % 8.36 % 23.74 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 75.76 % 81.01 % 90.65 % 64.03 % 93.14 %
Cash Flow Coverage Ratios TTM -463.27 % 43.13 % 22.35 % 12.02 % 7.93 % 148.65 %
Price To Free Cash Flows Ratio TTM -4.02 28.78 8.03 34.2 26.35 24.01
Price To Operating Cash Flows Ratio TTM -3.19 21.9 6.45 31.53 16.87 22.35
Price Cash Flow Ratio TTM -3.19 21.9 6.45 31.53 16.87 22.35
Income Statement (TTM)
QNTM ZTS TAK HLN TEVA NBIX
Revenue $0B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $-0B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 0% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $-0.01B $3.87B $1210.51B $2.51B $0.78B $0.64B
Net Income $-0.01B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -12.49 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
QNTM ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $5.39B $4517.23B $8.62B $16.3B $0.46B
Total Liabilities $0.01B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $0.01B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $0B $0B $382.4B $0.08B $0B $1.71B
Total Debt $0B $6.74B $5066.17B $10.1B $18.08B $0.46B
Total Assets $0.02B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
QNTM ZTS TAK HLN TEVA NBIX
Net Income $-0.01B $2.5B $107.93B $1.44B $-1.96B $0.34B
Inventory $-0B $-0.04B $-34.97B $0.22B $0.17B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $-0.01B $2.95B $1057.18B $2.3B $1.25B $0.6B
Capital Expenditure $0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.95
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.61
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 7.65
ALVOW Alvotech 1.25
AMPH Amphastar Pharmaceuticals, Inc. 25.5
AMRX Amneal Pharmaceuticals, Inc. 10.82
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 90.6
APUS Apimeds Pharmaceuticals US, Inc 2.19
AQST Aquestive Therapeutics, Inc. 6.82
ASRT Assertio Holdings, Inc. 0.7444
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 18.89
ETFs With Exposure to QNTM
Ticker ETF Name Weight Percentage Price
PSIL AdvisorShares Psychedelics ETF 2.94 19.9334
Unlock